UPDATE: Sanofi Supports GSK And Johnson & Johnson With Covid Vaccines

(Alliance News) - Sanofi SA and GlaxoSmithKline PLC initiated a new phase 2 study with 720 ...

Alliance News 22 February, 2021 | 11:17AM
Email Form

(Alliance News) - Sanofi SA and GlaxoSmithKline PLC initiated a new phase 2 study with 720 volunteers to select the most appropriate antigen dosage for phase 3 evaluation of their adjuvanted recombinant protein Covid-19 vaccine candidate, both companies said on Monday.

In parallel to the new phase 2 study and recognising the global emergence of new SARS-CoV-2 variants and their potential impact on vaccine efficacy, Sanofi has commenced development work against new variants which will be used to inform the next stages of the Sanofi/GSK development programme.

"Over the past few weeks, our teams have worked to refine the antigen formulation of our recombinant-protein vaccine, based on learnings from our initial phase 1/2 study," said Thomas Triomphe, executive vice president & head of Sanofi Pasteur.

"We look forward to further progressing this vaccine candidate to phase 3 in the second quarter of 2021, if this phase 2 study is successful," added Roger Connor, president of GSK Vaccines.

Sanofi shares were trading 0.3% lower in Paris on Monday at EUR76.82 each, while GSK shares were up 0.7% in London at 1,223.10 pence each.

Also on Monday, Sanofi said it has agreed with Janssen Pharmaceutical NV and Janssen Pharmaceuticals Inc, two Johnson & Johnson subsidiaries, to support manufacturing of Janssen's Covid-19 vaccine.

Janssen has submitted an application to the US Food & Drug Administration requesting emergency use authorization for its single-dose Janssen Covid-19 vaccine candidate and an application for conditional marketing authorisation to the European Medicines Agency.

Once authorized, Sanofi said it will provide Johnson & Johnson access to the established infrastructure and expertise of its vaccine manufacturing plant in Marcy l'Etoile, France, to formulate and fill vials of Janssen's Covid-19 vaccine candidate in 2021, at a rate of 12 million doses per month.

Johnson & Johnson shares closed 1.7% lower in New York on Friday at USD162.98 each and lost a further 0.9% in the pre-market trading on Monday.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
GlaxoSmithKline PLC 1,319.60
Sanofi SA 85.06
Johnson & Johnson 161.25

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement